Padza Padtan Pajhooh company was established in 2017 with the aim of providing production and research services in the field of antibodies as well as antigens. So far, several antibodies related to cancer cell markers and more than 80 monoclonal and polyclonal antibody products and their enzyme and fluorescence conjugates have been produced in the company. Currently, the company has a large number of antibody-producing hybridomas in its hybridoma bank, of which about 200 products are available for public sale.
The idea of CSC about cancer was proposed and the joint project between Avicenna Research Institute of Iran and Karolinska Institute of Sweden was proposed and preliminary studies were begun.
The project related to chronic lymphocytic leukemia (CLL) was started using 4 markers Ror1, PRELP, Opticin and Fibromodulin.
The first antibodies against the above-mentioned markers were produced by the Avicenna Research Institute in the Antigen Antibody Engineering Department, and the results were published in prestigious international journals.
Since 2006 to 2017
In total, about 600 clones related to almost 230 antigens were produced.
The knowledge-based company Padza Padtan Pezheh was established with the aim of transferring the new knowledge obtained from the university to the biotechnology industry.
2018 & 2019
beginning research projects in the field of cancer diagnosis using non-invasive methods
Development of diagnostic and therapeutic antibodies against COVID 19
Focusing on the humanization of mouse antibodies produced with its proven effects and conducting preclinical tests in animal models (mouse).
Why do people trust us
Attracting the trust of leading experts is by no means accidental. This trust is the result of years of work by an expert team from one of the best scientific research institutes in the country.